Experts say the medication is very promising, but it's still being studied and won't be available until it completes the FDA approval process. CVS Caremark is adding Zepbound, Eli Lilly's obesity drug, back to its commercial insurance plan formularies, more than a year after it stopped covering it in favor of Novo Nordisk's Wegovy. US Drug Spending: Where $603 Billion Goes, How IP Architecture Shapes Every Dollar, and What It Means for Pharma Investors DrugPatentWatch Transform Data into Market Domination Draconic Destruction Precon Primer EDHREC